7 completed, 1 withdrawn. 8 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 7, Withdrawn 1 |
Follow Mylan Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pharmacokinetics and Safety of Double-dose Dolutegravir When Used With Rifapentine for HIV-associated Tuberculosis Dolutegravir (DTG) 50 mg orally BID (~12 hours apart) plus TDF/3TC, DTG 50 mg orally QD plus TDF/3TC, 2HPZM - HIV-associated Tuberculosis | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 30 | 2024-02-13 | 2026-07-20 |
| Improving Beta-2 Adrenergic Signaling in Alzheimer's Disease Formoterol A, Formoterol B (placebo) - Alzheimer's Disease, Cognitive Dysfunction | Phase 2 | Withdrawn | Palo Alto Veterans Institute for Research | 2023-01-01 | 2020-09-16 | |
| Dose-Response Study of MR-107A-01 in The Treatment of Post-Surgical Dental Pain MR-107A-01, Placebo - Pain, Postoperative Pain | Phase 2 | Completed | Mylan Inc. | 114 | 2020-09-29 | 2022-08-08 |
| A 28-Day Parallel Group Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD) TD-4208, Placebo - COPD | Phase 2 | Completed | Mylan Inc. | 355 | 2014-05-01 | 2022-02-24 |
| A 7-Day Cross-over Study of QD (Once Daily) and BID (Twice Daily) TD-4208 in Chronic Obstructive Pulmonary Disease (COPD) TD-4208, Placebo - Chronic Obstructive Pulmonary Disease, COPD | Phase 2 | Completed | Mylan Inc. | 64 | 2014-04-01 | 2022-02-24 |
| A Dose Ranging Vehicle Controlled Study to Determine the Safety and Efficacy of Permethrin Foam, 5% and Permethrin Foam, 4% for the Treatment of Scabies Permethrin Foam 4%, Permethrin Foam 5%, Vehicle Foam - Scabies | Phase 2 | Completed | Mylan Inc. | 130 | 2014-04-01 | 2023-04-26 |
| 7 Days of TD-4208 in Subjects With Chronic Obstructive Pulmonary Disease TD-4208, Placebo - COPD | Phase 2 | Completed | Mylan Inc. | 62 | 2012-12-01 | 2022-02-24 |
| Effects of TD-4208 on FEV1 in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Placebo, TD-4208 700 μg, TD-4208 350 μg - Chronic Obstructive Pulmonary Disease, COPD | Phase 2 | Completed | Mylan Inc. | 32 | 2011-05-01 | 2022-02-24 |
Pulmonary Disease, Chronic Obstructive (4) · Acute Pain (1) · Alzheimer Disease (1) · Bronchitis, Chronic (1) · Cognitive Dysfunction (1) · Emphysema (1) · Pain (1) · Pain, Postoperative (1) · Parasitic Diseases (1) · Scabies (1)
revefenacin (4) · Ipratropium (1) · dolutegravir (1)
United States (5) · New Zealand (2) · Dominican Republic (1) · Honduras (1) · Puerto Rico (1) · South Africa (1) · Thailand (1)
Ahmad Salehi, M.D.,Ph.D. (1) · Susanne Vogt (1)